Untangling the Risks: Psychedelic Medicine for Addiction

Untangling the Risks: Psychedelic Medicine for Substance Use Disorder Recovery

A Clinically Honest Look at the Evidence, the Tensions, and the Real Risks

David Wiss, PhD, RDN, FMCP
Founder, FxMed Mental Health

The conversation around psychedelics and addiction has been stuck between two camps for too long: dismissed entirely, or hailed as a cure-all. The reality is more complicated than either framing allows.

In May 2026, I hosted a webinar designed to walk through that complicated middle honestly. To hold the genuine therapeutic promise and the legitimate risks in the same space. To name the tensions with abstinence-based recovery directly rather than soften them. And to be specific about safety — the contraindications, the medication interactions, and the distinctions between medicines that get flattened in mainstream coverage.

This post is the long-form companion to that webinar. It is written for clinicians trying to make sense of where this field sits today, and for patients and families who want a careful, dialectical treatment of the topic — not a sales pitch in either direction. I write this as a researcher and clinician working with treatment-resistant mental health — a vantage point that finds the polarized framing inadequate to what patients are actually navigating.

A Brief History: From William James to the Renaissance

The use of altered states for healing predates clinical research by centuries, but the modern scientific story is shorter than most people realize. In the early 1900s, William James — the father of American psychology — described the cure for “dipsomania,” what we now call alcohol use disorder, as fundamentally religious in nature. The etymology is suggestive on its own: alcohol is “spirit,” and the language of recovery has always reached for something larger than pharmacology.

Bill Wilson, the co-founder of Alcoholics Anonymous, sits at the center of this history in ways that most 12-Step communities do not talk about. Before getting sober, Wilson took belladonna — a powerful deliriant — and had a profound transcendent experience that became the experiential foundation for what is now Step 2. Decades later, in the 1950s, Wilson took LSD in Los Angeles at the VA psychedelic research program and wrote to his physician afterward that “all the assurances of my original experience were renewed and more.” He was convinced LSD could help other alcoholics and actively tried to incorporate it into AA. The group conscience said otherwise. The AA we know today reflects that decision rather than Wilson’s own clinical conviction.

The research that informed Wilson’s enthusiasm was not fringe science. After Albert Hofmann discovered LSD in Switzerland in the 1940s, researchers across North America began exploring therapeutic applications with significant institutional support. Humphry Osmond and Abram Hoffer began treating alcohol use disorder with LSD at the University Hospital in Saskatchewan in 1953, and the years that followed produced an almost exclusively Canadian program with consistently promising results [1]. By 1961, over 1,000 articles on LSD had appeared in mainstream medical journals — these were university hospitals and research centers, not underground labs [2].

A 1961 Canadian study captures the texture of this work well: 61 patients with alcohol use disorder who had been unsuccessful in AA received LSD combined with psychotherapy. At 3- to 18-month follow-up, half were much improved [3]. A 2012 meta-analysis of randomized controlled trials from this era — over 500 participants, single doses of LSD, mostly higher than what would be used today — found a significant decrease in alcohol misuse following treatment [4].

The first wave of psychedelic research did not end because the data turned negative. The 1970 Controlled Substances Act classified psychedelics as Schedule I — high abuse potential, no accepted medical use — driven largely by cultural politics rather than scientific evidence [2]. The Spring Grove research project in Maryland, the largest US psychedelic program at the time, continued until political pressure shut it down in the mid-1970s. The research silence that followed lasted decades.

What we now call the renaissance began quietly in the early 2000s. In the past 20 years, more than 2,000 peer-reviewed articles have investigated psychedelics for substance use disorder and other psychiatric conditions [2]. Federally funded psilocybin research at Johns Hopkins, regulatory breakthrough designations, and an April 2026 White House executive order on accelerating treatments for serious mental illness all signal that this is no longer a fringe conversation. It is becoming a mainstream clinical question. The relevant question now is not whether psychedelic medicine has a place in addiction care, but where, for whom, and on what terms.

The Medicines and How They Work

The compounds discussed under the umbrella of “psychedelics” are not pharmacologically uniform. Conflating them at the level of clinical decision-making is one of the most common mistakes in the public conversation, and one of the most consequential. They differ in their primary receptor targets, their duration of action, their abuse liability, and their drug interaction profiles. For someone with a substance use disorder history, those differences are not academic.

Classic psychedelics (serotonergic)

This category includes psilocybin (the active compound in psilocybin mushrooms), LSD, ayahuasca (a plant brew containing DMT plus a monoamine oxidase inhibitor that allows DMT to be orally active), 5-MeO-DMT (from the Sonoran Desert toad or synthesized), and mescaline (from peyote, San Pedro, and other cacti, or synthesized). Their primary mechanism is direct agonism at the 5-HT2A serotonin receptor, which is mechanistically distinct from SSRIs — those work by inhibiting serotonin reuptake rather than acting on receptors directly [5, 6]. Duration varies: psilocybin is typically 4 to 6 hours, LSD considerably longer, ayahuasca usually 4 to 6 hours within a long ceremonial container. DMT and 5-MeO-DMT in their non-ayahuasca forms are very short-acting — minutes to under an hour. The classic psychedelics show among the lowest abuse liabilities of any psychoactive substances [6].

Entactogens

MDMA is the prototype, with MDA as a related compound. MDMA is synthetic; MDA exists in plant form as well. These compounds activate serotonin, dopamine, and norepinephrine systems simultaneously, producing emotional openness and a reduced fear response. Most of the MDMA evidence base is in PTSD, which is highly comorbid with substance use disorder, so the indirect relevance is real. The dopaminergic activity also makes MDMA the most concerning entactogen for people with addiction histories — a point I return to below.

Dissociatives

Ketamine acts primarily by antagonizing the NMDA glutamate receptor, which alters extracellular glutamate and modulates corticolimbic connectivity. It is short-acting in clinical settings (about an hour intravenously or intramuscularly), already legal as an anesthetic, and increasingly used off-label for depression and as an emerging tool in substance use disorder treatment. It is also the most notorious of the medicines discussed here for non-medical use. Ketamine can become — and clinically I have seen it become — problematic for people with addiction histories.

Opioid-system: ibogaine

Ibogaine, derived from the iboga plant of West Africa, is the outlier. It interacts with the opioid system in a complex way: agonism at the kappa opioid receptor, which is associated with anti-reward signaling, alongside effects on the mu opioid system, which is the reward side. It produces a long experience — most of a day — and stays in the body even longer through its active metabolite. It shows the most prominent effects in the published evidence base for opioid use disorder specifically, and it carries the most significant medical risk profile, including documented cardiotoxicity. The safety details are in the contraindications section below.

Mechanisms: neuroplasticity, BDNF, and unlearning

What unifies these compounds at a mechanistic level is convergent: most of them appear to promote neuroplasticity — the brain’s capacity to form new synaptic connections and remodel existing circuits. Both serotonergic psychedelics and ketamine recruit growth factors including brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), with downstream synaptic remodeling that is particularly active in the prefrontal cortex — the region central to executive function and the weighing of consequences [7].

This matters for addiction in a specific way. Both trauma and addiction are characterized by cognitive rigidity — entrenched circuits, repetitive thoughts, behaviors that resist conscious effort to change. Neuroplasticity is the biological substrate of unlearning. The hypothesis under active investigation is that psychedelic-induced plasticity opens a window during which the patterns underlying addictive behavior become more amenable to change — provided the work of integration actually happens in that window. The medicines do not do the work themselves. They open a door.

Why the serotonergic / dopaminergic distinction matters

A practical takeaway across all of this: classic psychedelics are primarily serotonergic, not dopaminergic. For someone with a substance use disorder history, that distinction may be the single most important pharmacological detail in this conversation. Dopaminergic activation can recruit old patterns — what I sometimes describe with patients as the “dark cloud” of addiction history — in ways that serotonergic activation generally does not. MDMA and ketamine sit on the more dopaminergic side of the field. Classic psychedelics — psilocybin, ayahuasca, LSD when handled carefully — sit on the safer end for SUD populations. The dopamine question gets a fuller treatment below.

What the Evidence Shows for Substance Use Disorder

The evidence base is now substantial and growing. The patterns that emerge from systematic reviews and well-conducted trials are consistent enough to summarize, with the caveats that the next section covers in detail.

Alcohol use disorder

A 2022 randomized controlled trial published in JAMA Psychiatry compared psilocybin-assisted psychotherapy to placebo in adults with alcohol use disorder. The psilocybin group showed a significantly reduced percentage of heavy drinking days — the primary outcome — over the 32-week follow-up [8]. This sits alongside the 2012 meta-analysis of older LSD-for-alcoholism studies showing significant decreases in alcohol misuse after single doses [4]. The contemporary alcohol literature is smaller than the classical literature but converges on the same direction.

Tobacco use disorder

The Johns Hopkins group has produced some of the most striking results in the field, in a population that is particularly hard to reach: serious smokers, averaging a pack a day, with a mean of six prior failed quit attempts. In the open-label pilot, 80% of participants were biologically verified abstinent at 6 months following psilocybin combined with cognitive behavioral therapy [9]. At 12-month follow-up, two-thirds were still abstinent [10]. Larger controlled trials comparing psilocybin to nicotine replacement are underway, and the field rightly cautions against over-interpreting open-label data — but the magnitude of the effect in a treatment-resistant population is hard to dismiss.

Opioid use disorder

For opioid use disorder, two complementary lines of evidence exist. Ibogaine, despite its medical complexity, has the most prominent treatment effects in the published comparative literature. A 12-month follow-up observational study reported significant reductions in opioid withdrawal and use after a single ibogaine treatment [11]. The clinical consensus is that ibogaine can interrupt the addiction cycle but is not a cure — recovery remains an ongoing process that requires the rest of the work. On the population side, an analysis of National Survey on Drug Use and Health data found that classic psychedelic use was associated with 40% reduced odds of past-year opioid abuse and 27% reduced odds of past-year dependence [12]. A separate online survey of naturalistic psychedelic use documented persisting reductions in cannabis, opioid, and stimulant misuse [13].

Ketamine across substances

Ketamine has been studied across alcohol, cocaine, opioid, and nicotine use disorders. Recent systematic reviews report that ketamine reduces alcohol withdrawal symptoms and benzodiazepine requirements; decreases craving and increases abstinence in cocaine use disorder; and improves abstinence and reduces cravings in opioid use disorder when combined with therapy [14, 15]. The emerging consensus is that ketamine’s NMDA antagonism, with its downstream effect on extracellular glutamate, may benefit the corticolimbic connectivity disruption that keeps people stuck in addictive patterns.

Real-world data

A large electronic health record cohort study analyzing patients with documented SUD diagnoses found that psychedelic use was associated with significantly reduced rates of overdose, relapse, mental health crises, and hospitalizations compared to no treatment — particularly when combined with outpatient care [16]. Complementing this, a cross-sectional study of 466 individuals with chronic pain found that 86% reported ceasing or decreasing use of one or more non-psychedelic substances following psychedelic use, with 21% indicating these changes persisted for more than 26 weeks [17]. Observational data must always be interpreted carefully, but the consistency of direction across very different study designs adds meaningful context to the controlled trial results.

What the meta-analyses show

Pulling back to the meta-analytic level: serotonergic psychedelics and MDMA show moderate to large effect sizes for PTSD, depression, and anxiety disorders [18]. The substance use disorder findings are more variable across substances, but the recent SUD-specific meta-analysis identified ibogaine as having the most prominent effects, with large effect sizes for opioid dependence specifically [19]. Across the broader review literature, the recurring message is that the best outcomes appear when psychedelic administration is combined with structured psychotherapy, not delivered as a stand-alone medication [20].

The summary judgment from this evidence base is not that psychedelics work for everyone with substance use disorder. It is that the signal is real, the magnitudes are clinically meaningful, and the field has matured beyond dismissing the question. The harder questions are about who benefits, who does not, what the limits of the data are, and how this gets implemented responsibly. Those questions are the next several sections.

The Limits of the Evidence

A serious treatment of this literature has to name the limits clearly, because the gap between the controlled-trial evidence base and the actual patients who walk into substance use disorder treatment is wide. Several issues deserve specific attention.

Trial exclusion criteria vs. real-world patients

The published trials are run on heavily selected populations. Most studies exclude participants with personal or family history of psychosis, active suicidal ideation, current mood episodes, recent active polysubstance use, and concurrent psychotropic medications [21]. Those exclusions are appropriate from a research-safety standpoint. They also mean the trial populations look almost nothing like the patients I see clinically. Most adults with substance use disorder carry one or more of those exclusion criteria. The literature is built on the cleanest cases. The hardest cases — the patients most likely to be sent to a clinic asking about psychedelic options — are the ones with the least published data.

Control and blinding challenges

Functional unblinding is near-total in psychedelic trials. Both participants and assessors typically know within minutes whether the active medicine has been administered. Active controls (low-dose niacin, methylphenidate, midazolam) reduce but do not eliminate this problem, and the field is still working through how meaningfully the placebo response can be quantified when expectancy effects are this strong [22]. This does not invalidate the findings, but it does mean that the effect-size estimates from these trials should be read with that caveat in mind.

Demographic gaps

The clinical trial populations skew heavily white, educated, and middle-class. Women remain meaningfully underrepresented across the field — a recent scoping review of 75 SUD-relevant studies found that 46 had female representation below 45% and 9 included no women at all [23]. Sex differences in addiction patterns and treatment response are well documented. The current evidence base does not yet support confident generalization across sex, race, or socioeconomic position.

Sample size and replication

Most SUD-specific psychedelic trials have small samples — often under 100 participants, frequently under 30. A few have approached or crossed the 100 mark. Large multi-site trials are emerging but have not yet matured. Independent replication of headline findings remains in progress for most of the substance use disorder–specific results [24].

Publication bias

Publication bias is a structural feature of any field where research programs and commercial interests overlap. When a sponsor with commercial interests in psychedelic medicalization produces unimpressive results, the incentive to publish is lower than when the result confirms the hypothesis [21]. The current literature should be read with that asymmetry in mind. Negative findings exist; they may be underrepresented in what reaches PubMed.

The honest summary

The signal is real. The effect sizes in well-conducted trials are clinically meaningful. The convergence across very different study designs — randomized controlled trial, observational, naturalistic survey, electronic health record cohort — is a stronger evidentiary pattern than any one study type would produce alone. But the evidence base supporting psychedelic medicine for substance use disorder is narrower than mainstream coverage often suggests. It is built largely on selected populations, smaller sample sizes than the public conversation implies, and a body of work that the field itself is actively working to expand and rigorize [22, 24]. The right posture is cautious clinical engagement, not confident extrapolation.

The Tension With Abstinence-Based Recovery

This is where the conversation gets uncomfortable, and where the polarized framing has done the most damage. The traditional 12-Step view is that sobriety equals abstinence from all mind-altering substances, full stop. Within that frame, psilocybin equals relapse. Ayahuasca equals relapse. Ketamine — even when prescribed — equals relapse. The position has clarity, history, and deep cultural authority. It has also kept many people alive.

It is also incomplete in ways the field needs to discuss honestly.

The “a drug is a drug” framing and what it leaves out

The “a drug is a drug” position is a practical heuristic. It collapses a wide pharmacological range — caffeine to methamphetamine to psilocybin — into a single category for the purpose of building a stable behavioral commitment. For someone in early recovery, that simplification is often life-saving. The problem is when the heuristic is taken as a pharmacological claim rather than a behavioral one. Psilocybin and methamphetamine are not the same compound, do not produce the same neurobiological effect, and do not carry the same abuse liability. The serotonergic classics show among the lowest abuse liabilities of any psychoactive substances [6]. The framing that treats all of them as equivalent operates at the level of identity rather than evidence — and it produces real consequences for people whose recovery has plateaued.

I have seen patients internalize the equation in ways that close off paths they might otherwise have taken. The internal voice — if I take this, I’m not really sober — is loud, and for someone whose identity has been rebuilt around abstinence over years or decades, the threat to that identity is not abstract. It can override what the data actually says about a particular medicine in a particular context.

Bill Wilson’s actual position

The historical record on this is clearer than 12-Step culture often acknowledges. Bill Wilson did not believe the framing that AA later adopted. After his 1956 LSD experiences within the VA psychedelic research program, he wrote to his physician that the experience renewed and amplified the original spiritual awakening that founded his sobriety. He believed LSD could help other alcoholics achieve the same kind of breakthrough. He pursued incorporation actively. The AA group conscience overruled him. The decision was about institutional risk and public perception in a politically charged decade — it was not about clinical evidence. The current 12-Step orthodoxy on psychedelics is not what the founder believed; it is what the institution decided to formalize over his objection.

Mystical experience and the part of the literature hardest to reconcile

The published literature has converged on a finding that is genuinely difficult to reconcile with a strict abstinence framing: in psychedelic-assisted treatment for substance use disorder, the magnitude of the mystical or profound subjective experience during the session correlates with the magnitude of the clinical outcome [8]. The thing the medicine produces — a phenomenological event participants describe in language remarkably similar to the “hitting bottom” or spiritual-awakening moments AA literature has always treated as central — is the active ingredient in the therapeutic effect. Treating that experience as a relapse, when it is the very thing the recovery tradition has always pointed toward, could be a categorical error.

A recent paper makes this explicit, framing psychedelic-assisted treatment as a potential augmentation of 12-Step engagement rather than a competitor to it [25]. The qualitative work in Indigenous Canadian communities using ayahuasca-assisted retreats describes participants finding “their spirit back” in language that overlaps directly with recovery testimony [26]. The medicines and the tradition appear to be reaching for the same destination by different routes.

The risk of not offering safer pathways

The standard risk framing in recovery circles is one-directional: the risk of introducing psychedelic medicine. The other direction — the risk of not introducing it, of insisting on abstinence as the only acceptable answer — is rarely named with the same seriousness. People die in long-term recovery. They die by suicide after 10, 20, 30 years sober, having done the work and still found themselves in pain the tradition could not reach. They die from the comorbidities that drove the addiction in the first place — depression, complex trauma, chronic anxiety — when those underlying conditions never resolved. They die quietly, often, having shown up to meetings every week and been technically successful by the metric the tradition measures.

The published evidence base does not yet tell us how many of those deaths might have been prevented by access to well-supported psychedelic-assisted care. The honest answer is that we do not know. But the bias toward only counting the risks of action, while treating the risks of inaction as natural and unaccountable, is not neutral. It is a clinical judgment dressed as caution.

What this section is not arguing

It is not arguing that everyone in recovery should pursue psychedelic medicine. The contraindications are real; the medicine is not the work; the population for whom this is appropriate is narrower than enthusiasts claim. Those points are made directly in the safety section that follows.

What it is arguing is that the “a drug is a drug” framing collapses distinctions that matter, that Bill Wilson’s actual position is not the position the tradition holds, that the mystical-experience literature reaches for the same territory recovery has always pointed at, and that the failure to offer well-supported access carries its own measurable cost. Holding all of this honestly is the price of clinical credibility on this topic.

Why Dopamine Matters: The Addiction-Specific Concern

The most clinically actionable distinction in this entire field, for someone with a substance use disorder history, is between primarily serotonergic and primarily dopaminergic activation.

Dopaminergic activation can recruit the old patterns of addiction. The biology of substance use disorder centers on dysregulation of mesolimbic dopamine signaling — the same circuit any dopaminergic substance touches. For a person whose nervous system has been shaped by years of substance-driven dopamine surges, even a single dopaminergic event can re-prime the craving and compulsion architecture in ways that are difficult to predict and harder to undo. This is not theoretical. It is the experience clinicians who work with this population describe consistently, regardless of whether the dopaminergic event came from a ceremonial plant, a clinical infusion, or a recreational compound.

Classic psychedelics — psilocybin, LSD, ayahuasca, mescaline, 5-MeO-DMT — act primarily through serotonin 5-HT2A agonism, with minimal direct dopaminergic effect, and show among the lowest abuse liabilities of any psychoactive substances [6]. MDMA and ketamine are different. MDMA’s profile includes substantial dopaminergic and adrenergic activity. Ketamine has a documented non-medical use pattern that, in clinical practice, I have seen become problematic specifically for people with addiction histories. Both can be used responsibly within the right clinical framework. They are also the medicines I am most cautious about recommending in this population.

There is a separate addiction risk that does not appear on standard pharmacology charts: addiction to non-ordinary states themselves. Even with primarily serotonergic medicines that carry essentially no traditional abuse liability, patients can develop a compulsive relationship with the experience — chasing ceremonies, escalating frequency, treating each session as the substitute for the integration work that is supposed to happen between sessions. The medicines, in that mode, become another form of bypass. The work is not the ceremony. The work is what happens after, every day.

Safety, Screening, and Contraindications

The safety profile of psychedelic medicine is genuinely better than mainstream coverage often implies. It is not, however, uniformly benign across substances or populations. The screening that matters happens in five areas.

Serotonergic interactions

The drug-interaction concern that needs the most clinical attention is the serotonergic one. Ayahuasca by design includes monoamine oxidase inhibitor activity — that is what allows the DMT in the brew to be orally bioavailable. Combining DMT or 5-MeO-DMT with MAOIs in non-traditional ways can be potentially fatal. For patients on prescribed SSRIs or SNRIs, the interaction question depends on the specific medicine and the protocol. Some current psilocybin protocols are beginning to allow concurrent SSRI use rather than requiring full taper, on the basis of emerging tolerability data. Other compounds and other settings still require supervised tapering completed well in advance. The decision is medication-specific and protocol-specific. It should not be made by the patient alone.

Psychiatric screening

The exclusion criteria the published trials use exist for clinical reasons, not bureaucratic ones. Active psychosis, personal or family history of psychotic disorders, active mood episodes, active suicidal ideation, and concurrent psychotropic medications are the recurring exclusions [21]. For someone with a substance use disorder history specifically, the rate of overlap with these criteria is substantial — depression, complex trauma, anxiety, and prior suicidality are common in this population. The presence of any of these does not automatically rule out the work; it does mean the screening needs to be more thorough, not less, and that some patients will appropriately be told this is not the right intervention at this time. Many experts agree that ketamine can be particularly effective for suicidal ideation. Some people should not use any psychoactive substance, and the abstinence trajectory remains the right answer for them.

Cardiac screening, especially for ibogaine

Ibogaine’s cardiotoxicity is the most significant medical risk in this entire category. The published mortality is rare in absolute terms but real, and the documented deaths in the literature have most often involved polysubstance use or deviations from established protocol [11, 27]. ECG screening before any ibogaine treatment is non-negotiable. The same level of cardiac caution does not apply to the classic serotonergic psychedelics, but it does mean that any clinical setting offering ibogaine without comprehensive cardiac evaluation should be considered unsafe. The waiting lists at the established Mexican ibogaine clinics reflect, in part, the medical screening rigor those programs require.

Recent active use vs. history of use

There is an important distinction between a patient with a substance use disorder history who has built durable sobriety and a patient with active or very recent use. The former population is the one the published research is approaching. The latter is a different clinical situation entirely — physiologic vulnerability is higher, integration capacity is lower, and the published evidence does not extend to that group. A meaningful sober interval before any psychedelic exposure is the standard expectation across reputable protocols.

Practitioner qualifications and the unregulated-market gap

The current legal landscape is uneven. Some states have decriminalized or legalized certain compounds; ketamine clinics now operate openly in most US markets and increasingly mail product to patients at home; ibogaine retreats run in adjacent jurisdictions. The medicine in these settings may be real. The clinical container often is not. Patterns from prior episodes of pharmaceutical normalization — cocaine and heroin in the early 1900s, doctors endorsing cigarettes in the 1950s, OxyContin in the late 1990s — are worth noticing. The risk of repeating that arc with these compounds is real, and the safeguard is the practitioner. Look for documented training in psychedelic-assisted therapy; medical screening that includes cardiac, hepatic, psychiatric, and medication-interaction evaluation; integration support built into the structure rather than offered as an upsell. Decriminalized access without those safeguards is not the same as clinical care. For a population with substance use disorder history, the difference is consequential [22].

If you or a patient is navigating these questions in the context of treatment-resistant mental health symptoms, FxMed Mental Health offers comprehensive functional medicine evaluation as the foundation for safe psychedelic-assisted care. Schedule a free discovery call to explore whether the program is the right fit.

14 Considerations for People in Recovery Considering Psychedelic-Assisted Care

These guidelines reflect the intersection of the published evidence and my clinical work with patients navigating this question. They are offered as expert synthesis — tools for thinking, not a checklist that substitutes for individualized assessment.

Phase 1 — Decision and Pathway

1. Three pathways exist; only two should be considered. Medical (clinical, regulated, supervised), ceremonial (traditional setting, trained practitioners, structured container), and recreational (self-directed, unsupervised). For someone with a substance use disorder history, medical and ceremonial can be appropriate. Recreational is typically not.

2. Never serve yourself the medicine. Do not keep it, do not hold it, do not make the dosing decision. Let someone else with appropriate training do that. The act of self-administration is the addictive pattern wearing therapeutic clothing.

3. Complete a thorough medical screening before anything else. Comprehensive lab evaluation across the systems that determine readiness — gut, HPA axis, inflammation, nutrient status, cardiovascular, hepatic, psychiatric. The exclusion criteria the trials use exist for reasons; some apply to you and you do not yet know which.

4. Understand medication interactions and the tapering required. Tapering, when indicated, must be supervised and completed well before any session. Do not abruptly discontinue prescribed medications without guidance.

Phase 2 — Preparation

5. The on-ramp is several months to a year. Talk to experienced people. Watch the documentaries. Learn the history. Sit with your intentions. Get the functional medicine workup done. Rushing the preparation is the most reliable way to undermine the outcome.

6. Give something up before the session. A dieta — abstaining from caffeine, nicotine, sugar, or another habitual behavior in the weeks before — is structurally protective for someone with an addictive history. If giving something up for two weeks feels impossible, that is itself diagnostic information about readiness.

7. Expect that difficult experiences are possible and often therapeutic. Difficult does not mean bad. The fear, grief, and somatic activation that can surface during a session are usually part of the work, not signs the work has gone wrong.

8. Have an emergency plan in place before the session. Crisis line numbers. A trusted person on call. A clear plan if prolonged distress, suicidal ideation, or psychiatric destabilization emerges in the days following. Knowing the safety net is in place lets you surrender more fully.

Phase 3 — Disclosure and Integration

9. Do not keep secrets, but not everyone needs to know. Someone who understands your full history should know — therapist, sponsor, partner, trusted friend. Secrecy breeds shame and undermines integration. Disclosure to people who will not understand the path can cost you support you need. Choose your confidants deliberately.

10. Respect the teachings. The medicines amplify lived experience and reveal patterns; they do not deliver answers. Do not make major life decisions in the immediate aftermath. Translate insight into action gradually, with input from your integration support.

11. If the same message keeps returning because you have not done the work, pause. Repetition without action is a sign to stop returning to the medicine and return to the work the medicine was pointing you toward.

Phase 4 — Long-Term Sustainability

12. Build a real integration container around each session. Several days of lighter scheduling. Discussion with at least two people in your support network. Ongoing work with an integration specialist. The days and weeks after are where lasting change is built or lost.

13. Frequency matters; less is more. For classic psychedelics, a few times per year is a reasonable ceiling. More than quarterly is an early warning sign. Monthly is a clear indicator that something has gone off course. The more you find peace only with the medicine, the harder it becomes to find without.

14. Stay in both communities. Spiritual or psychedelic communities will likely include people who do not understand addiction. Recovery communities will likely include people who do not accept psychedelics. Leaving the recovery community for the psychedelic one is one of the most reliable failure patterns I have observed.

Where Functional Medicine Fits

The clinical question I started asking after attending the IFM conference in May 2025 was a practical one: if psychedelic-assisted therapy is going to be a meaningful part of mental health care over the next decade, what does the surrounding clinical infrastructure need to look like? The answer that emerged is that the medicine is not the work — the medicine opens a door. The work happens in the months of preparation before and the months of integration after. That before-and-after is where functional medicine fits.

Biological readiness as preparation

The body you bring to a psychedelic session shapes the experience the session produces. A nervous system primed for threat detection by chronic inflammation responds differently than one that is not. A body running on dysregulated cortisol stays in survival mode whether you want it to or not. Metabolic and gut function shape what neurotransmitters are available and what mood states are accessible. None of this is metaphor; it is measurable biology that comprehensive functional testing can map. Patients who arrive at psychedelic-assisted care with significant unaddressed gut dysfunction, HPA axis dysregulation, or active inflammation are at higher risk for difficult experiences and lower likelihood of durable integration. The work of biological readiness is real preparation, not adjunct.

The IFS / functional medicine parallel

Internal Family Systems and functional medicine make the same argument from different directions. IFS says there are no bad parts — every internal protector, even the ones that binge, withdraw, rage, or shut down, is doing a job and carrying a burden it did not choose. Functional medicine says there are no bad symptoms — fatigue, inflammation, hormonal chaos, gut dysfunction are signals, not enemies. Both frameworks ask the same question: what is this trying to do for me, and what does it need?

The two systems also interact materially. Your biological state determines which internal parts come forward. Chronic inflammation primes the nervous system for threat detection. Dysregulated cortisol keeps the body in survival mode. A body that is metabolically on fire makes the exiles harder to contain and the firefighters harder to quiet. You cannot do clean IFS work, or clean psychedelic work, in a body that is under siege. The biology and the psychology are the same problem viewed from different angles.

How this looks at FxMed Mental Health

At FxMed Mental Health, we work with patients whose conventional mental health care has stopped producing results — the population we describe as treatment-resistant or undertested. The work is comprehensive lab evaluation across blood, urine, stool, and saliva, mapped across systems to identify what is actually driving the clinical picture, structured into a six-month protocol with three phases of active intervention. The shorter primer on psychedelic medicine and substance use disorder — covering the harm-reduction frame and the basic safety profile — is at Psychedelic Medicine and Substance Use Disorder Recovery. For broader context on other supportive sources of nourishment, see Plant Allies for the Psychedelic Journey. The trauma biology side — particularly the intergenerational dimension that surfaces frequently in psychedelic-assisted work — is covered in Can Generational Trauma Influence Detoxification Capacity?.

The frame is consistent across all of this: biological dysfunction is measurable, mental health is physical health, and the work of healing has a substrate that needs to be supported.

Frequently Asked Questions

Are psychedelic medicines safe for people in recovery from substance use disorder?

Classic psychedelics — psilocybin, LSD, ayahuasca, mescaline, 5-MeO-DMT — are generally considered safer for people with substance use disorder histories than MDMA or ketamine because they act primarily on serotonin rather than dopamine. Safety depends on the specific medicine, the medical and psychiatric screening completed beforehand, the qualifications of the practitioner administering it, and the integration support that follows.

That said, some people should not use any psychoactive substance regardless of medicine class. Active mood episodes, personal or family history of psychosis, recent active substance use, and certain cardiac and medication-interaction profiles are among the standard contraindications. Comprehensive cardiac, hepatic, psychiatric, and medication-interaction screening should precede any decision about pursuing this work.

Will using psychedelic medicine clinically cause me to relapse?

For someone with a substance use disorder history, the relapse risk depends primarily on where someone is on their spiritual path, life circumstances, as well as whether the medicine is dopaminergic (higher concern) or serotonergic (lower concern), and on whether the use occurs within a properly structured clinical or ceremonial container with integration support. Classic serotonergic psychedelics show among the lowest abuse liabilities of any psychoactive substances and do not typically activate the dopaminergic craving circuits central to addiction.

There is a separate addiction risk that does not appear on standard pharmacology charts: addiction to the non-ordinary state itself. Patients can develop a compulsive relationship with the experience, escalating frequency and bypassing the integration work the medicine was meant to support. Frequency limits and integration discipline matter as much as the medicine class.

What is the difference between classic psychedelics, MDMA, and ketamine for someone with an addiction history?

Classic psychedelics (psilocybin, LSD, ayahuasca, mescaline, 5-MeO-DMT) act primarily on serotonin 5-HT2A receptors with minimal direct dopaminergic effect. MDMA activates serotonin, dopamine, and norepinephrine simultaneously, with a more concerning abuse profile for people with addiction histories. Ketamine acts on NMDA glutamate receptors and is the medicine in this category most commonly associated with non-medical use patterns.

All three categories have legitimate clinical applications. The question for someone with an addiction history is not which medicines work — all of them have published evidence — but which carry the lowest risk of recruiting old patterns. The classic serotonergic psychedelics generally do; MDMA and ketamine require more careful consideration in this population.

Why does the dopamine vs. serotonin distinction matter so much for SUD?

The biology of substance use disorder centers on dysregulation of mesolimbic dopamine signaling — the brain circuit that drives craving and compulsive use. Any substance that activates dopamine touches this circuit. For someone whose nervous system has been shaped by years of substance-driven dopamine surges, dopaminergic activation from any source can re-prime craving and compulsion patterns that take significant time to settle.

Serotonergic activation operates on a different system. The classic psychedelics produce profound subjective and therapeutic effects through 5-HT2A agonism without recruiting the dopaminergic addiction circuitry. This is why pharmacological category matters more than legal status or marketing language for clinical decision-making in this population.

Can I use psychedelic medicine if I am taking an SSRI or SNRI?

The answer is medication-specific and protocol-specific, and the decision should always be made with a supervising clinician — not unilaterally by the patient. Some current psilocybin protocols are beginning to allow concurrent SSRI use rather than requiring full taper, on the basis of emerging tolerability data. Other compounds and other settings still require supervised tapering completed well in advance.

Ayahuasca is a special case — it includes monoamine oxidase inhibitor activity by design, which creates serious interaction risk with serotonergic medications. DMT and 5-MeO-DMT combined with MAOIs in non-traditional ways can be potentially fatal. Drug-interaction evaluation by a clinician with psychedelic medicine training is non-negotiable.

How does functional medicine support psychedelic-assisted care, before and after?

Functional medicine identifies and addresses the biological systems — gut, HPA axis, inflammation, nutrient status — that determine readiness for psychedelic-assisted care and shape the integration window after. The body you bring to a session influences the experience you have. Comprehensive functional testing before treatment maps what is driving the clinical picture; targeted interventions during the on-ramp prepare the substrate; ongoing functional support during integration helps consolidate change.

Patients arriving at psychedelic-assisted care with significant unaddressed gut dysfunction, HPA axis dysregulation, or active inflammation are at higher risk for difficult experiences and lower likelihood of durable integration. The medicine opens a door; biological readiness determines whether the room beyond it is one you can stay in.

Conclusion

The conversation around psychedelic medicine and substance use disorder will not resolve into a single position, and the patients best served by the field are the ones who learn to hold the dialectic rather than collapse it. The evidence is real. The risks are real. The published trials show clinically meaningful effects in carefully selected populations. The exclusion criteria reflect the populations most likely to be harmed. Bill Wilson believed in this work; the institution that bears his name does not. Mystical experiences correlate with the outcomes recovery has always pointed toward. Some people should not pursue this medicine at all. All of these are simultaneously true.

What the field needs now is clinical infrastructure that takes both halves of this seriously: comprehensive medical and psychiatric screening before any session; functional evaluation of the biological systems that determine readiness; supervised tapering of interacting medications; integration support that begins before the medicine and continues for months after; and the willingness to tell some patients honestly that this is not the right intervention at this time.

At FxMed Mental Health, we built our six-month program to be that infrastructure. Comprehensive lab evaluation across blood, urine, stool, and saliva. Three phases of active intervention mapped to the systems driving the clinical picture. Practitioner-coordinated care across nutrition, integrative psychiatry, and somatic work. The premise underneath all of it is simple: mental health is physical health, and you are not treatment-resistant — you are likely just undertested.

If you are navigating these questions for yourself or a patient, schedule a free 15-minute discovery call to explore whether the program is the right fit.

About the Author

Dr. David Wiss, PhD, RDN, FMCP, is a functional medicine practitioner specializing in treatment-resistant mental health conditions. His work integrates nutritional psychiatry, advanced functional testing, and root-cause clinical evaluation to identify the biological drivers of depression, anxiety, addictive disorders, and other psychiatric conditions. He is the founder of FxMed Mental Health and has undergone training in psychedelic-assisted therapy through the Integrative Psychiatry Institute.

Disclaimer

This article is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information presented here should not be used to start, stop, or change any medication or treatment regimen. Several of the substances discussed — including psilocybin, LSD, MDMA, DMT, 5-MeO-DMT, mescaline, and ibogaine — are Schedule I drugs under US federal law. Ketamine is a Schedule III controlled substance available only by prescription. Legal status varies by state and jurisdiction. Decisions about psychedelic-assisted care should always be made in consultation with qualified medical and mental health professionals operating within applicable legal frameworks.

References

[1] Dyck E. Flashback: psychiatric experimentation with LSD in historical perspective. Can J Psychiatry. 2005;50(7):381-388.

[2] Nichols DE. The history of psychedelics in psychiatry. Pharmacopsychiatry. 2020;53(3):77-84.

[3] MacLean JR, MacDonald DC, Byrne UP, Hubbard AM. The use of LSD-25 in the treatment of alcoholism and other psychiatric problems. Q J Stud Alcohol. 1961;22:34-45.

[4] Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26(7):994-1002.

[5] Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21(11):611-624.

[6] Nichols DE, Barker EL. Psychedelics. Pharmacol Rev. 2016;68(2):264-355.

[7] Palhas AP, Bhatt DG, Bhatt S. Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction. Front Neurosci. 2025.

[8] Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry. 2022;79(10):953-962.

[9] Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983-992.

[10] Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017;43(1):55-60.

[11] Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.

[12] Pisano VD, Putnam NP, Kramer HM, Franciotti KJ, Halpern JH, Holden SC. The association of psychedelic use and opioid use disorders among illicit users in the United States. J Psychopharmacol. 2017;31(5):606-613.

[13] Garcia-Romeu A, Davis AK, Erowid E, Erowid F, Griffiths RR, Johnson MW. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey. Front Psychiatry. 2020;10:955.

[14] Janssen-Aguilar R, Lopez-Canul M, Bhardwaj SK, et al. Role of ketamine in the treatment of substance use disorders: a systematic review. J Clin Med. 2025.

[15] Thomas AL, Bhattacharjee S, Oritz RJ, et al. Ketamine’s therapeutic role in substance use disorders: a narrative review. J Clin Med. 2025.

[16] Qeadan F, McCunn A, Engard B. Associations between psychedelic use and adverse outcomes in substance use disorders: a real-world EHR-based cohort study. J Psychiatr Res. 2025.

[17] Glynos NG, Goel N, Engel-Smith B, et al. Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use. Front Pain Res. 2025.

[18] Højlund M, Andersen K, Østermark J, et al. Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: a living systematic review with meta-analysis. Lancet Psychiatry. 2025.

[19] Keighley EE, Hamza EA, Bedewy DA, Nalla S, Moustafa AA. A systematic review and meta-analysis investigating the efficacy of various psychedelic drugs for the treatment of substance use disorder. Healthcare. 2025;13(21):2668.

[20] Hogea LM, Nussbaum LA, Antal A, et al. The therapeutic potential of psychedelics in treating substance use disorders: a review of clinical trials. Front Psychiatry. 2025.

[21] Gomez-Escolar A, Garcia-Romeu A. Current perspectives on the clinical research and medicalization of psychedelic drugs for addiction treatments: safety, efficacy, limitations and challenges. Curr Addict Rep. 2024.

[22] Propes CR, Olson DE, Barnett BS. Gaps in US psychedelic research and how to close them. JAMA Psychiatry. 2025.

[23] Nigri A, Cippitelli M, Ferrara M. Psychedelics for substance use disorders: are women being addressed? A scoping review. J Psychopharmacol. 2025.

[24] Lynch JL, Anderson BT, Smith-Apeldoorn SY. Addressing US demand for psychedelic medicines in the face of scientific uncertainty. N Engl J Med. 2025.

[25] Mehtani N, Garcia-Romeu A, Johnson MW. Psychedelic augmentation of 12-Step engagement: a novel, accessible approach to enhance community-based recovery from substance use disorders. J Subst Abuse Treat. 2025.

[26] Argento E, Capler R, Thomas G, et al. Exploring ayahuasca-assisted therapy for addiction: a qualitative analysis of preliminary findings among an Indigenous community in Canada. Drug Alcohol Depend. 2019;199:33-41.

[27] Kopra EI, Ferris J, Dargan PI, et al. Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022). J Psychopharmacol. 2025.